chemXplore tracks 3 projects in Korea (South), of which 3 are active.
Of the active ones, 2 expansion.
The dates themselves, per project, are for subscribers.
Upstream work finished at a 4,000 m Argentina site, raising commercial carbonate output to 48,000 t/year and enabling a 50,000 t/year lithium hydroxide system when linked to a 2027 downstream plant.
Long-term deal more than doubles prior volumes, expands supply from NCA to LFP, LMO and synthetic graphite, and secures non‑PFE materials for buyers.
HyREX demo (300,000 t/yr by 2028) in Pohang; TIMUP public‑private plan; targets KRW 6 trillion, 14,000 jobs and 560,000 t/yr CO2 reduction in the Southeastern cluster.
Post‑hoc ATTAIN‑1 modelling: oral orforglipron cut predicted 10‑year type 2 diabetes risk up to 57% and cardiovascular risk up to 18% versus placebo at 72 weeks.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
EU launches anti-dumping probe after PVC imports doubled in 12 months; industry urges faster provisional measures, safeguards and more DG Trade resources to protect European production.
Wholly owned Korea subsidiary to secure marketing authorizations and build phased in‑house sales for pipeline drugs including sparsentan and NXT007.
Develop next‑generation ABS/EP composites, expand PCR material use for interior/exterior parts, and run joint R&D and feasibility studies.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
KRW 480 billion investment for a 450,000 t/yr continuous galvanizing line at Gwangyang; EAF‑linked lower‑carbon, extra‑wide products and AI/robotics for quality and safety.
